PULSE Challenge: Catalysis – A guiding principle for biochemistry and professional career development
February 24, 2026 @ 15:00 – 16:00 CET
This seminar will describe Dr. Lorenz M. Mayr‘s experience in drug discovery from over 30 years in industry, academia, venture capital/financing and finally running Biotech startup companies. He is driven by his passion for science, interdisciplinary research and impact for patients. The ultimate goal has always been to bring innovative, impactful and affordable medicine to patients. He has had success by working in Germany, US, UK, Sweden and Switzerland, but also made a number of mistakes. Quote: I am happy to share my experience and to help new entrepreneurs to pursue a career in drug discovery, at academia or industry, but ideally with novel startup companies.
Host: Kristian Sandberg
Moderator: Anna Ridderstad
The seminar series PULSE Challenge is connected to the MSCA co-funded* postdoctoral program SciLifeLab PULSE, that will train 48 future leaders in life sciences. The program focuses on innovative, fundamental and translational research carried out in supportive and diverse academic and industrial environments, preparing postdocs with necessary skills for long-term career sustainability. Click HERE to find out more about SciLifeLab PULSE
On-line event via Zoom
Presenter:
Dr. Lorenz M. Mayr
Biography:
Lorenz is working as Managing Director at BioMedTech Consulting GmbH in Basel, Switzerland. The company provides consulting service to BioPharma, Biotechnology and MedTech companies and academic institutions. He is also working as Chief Executive Officer (CEO) and Chairman of the Board (President) of PHiNE Bio AG, a new Biotech startup company in Basel, Switzerland which is operating since 08/2025 in stealth mode and financed by private investors.
Lorenz has long-lasting experience in Pharma/Biotech investments and company creation from his work at Syncona Ltd (London, UK), Hevolution Foundation (Boston, MA) and EIT-Health Gold Track (Boston, MA; Munich, Germany). Lorenz is a highly respected biopharmaceutical executive with extensive experience over the last 30 years in drug discovery, technology and innovation, business growth and financing strategy.
He has previously worked as a Chairman, Non-Executive Director, Chief Executive Officer, Chief Technology Officer, and Entrepreneur-in-Residence in the Biotech, Medtech, Pharma and Venture Capital industry across Europe and the US.
He has received first class degrees in biochemistry, biophysics, molecular & cell biology at the University of Tubingen (Germany), University of Bayreuth (Germany) and the University of Colorado at Boulder (U.S.A.) and a number of fellowships & awards for his studies in Germany and the United States.
Lorenz currently serves on the Board of Directors at Fundamental Pharma (Heidelberg, Germany), InCephalo (Basel, Switzerland) and PHiNE Bio AG (Basel, Switzerland), and serves on the Scientific Advisory Board of Fraunhofer IGB (Stuttgart, Germany), Fraunhofer IZI (Leipzig, Germany), SaxoCell (Leipzig), The Francis Crick Institute (London, UK), Science4Life (Stockholm, Sweden) SensibleBio (Oxford, UK), Hemotune (Zurich, Switzerland), Huidagene (Shanghai, China), AstraGenomics (Shanghai, China), TQ Therapeutics (Munich, Germany), GeneFab (San Francisco, CA) and NanoVation (Vancouver, Canada), and works as Senior Healthcare Advisor to EQT Investments (Stockholm/Sweden).
Google Calendar 
